Familial combined hyperlipidemia is a polygenic trait

Curr Opin Lipidol. 2022 Apr 1;33(2):126-132. doi: 10.1097/MOL.0000000000000796.

Abstract

Purpose of review: : Familial combined hyperlipidemia (FCH), defined by concurrently elevated plasma triglyceride (TG) and low-density lipoprotein (LDL) cholesterol, has long been investigated to characterize its genetic basis. Despite almost half a century of searching, a single gene cause for the phenotype has not yet been identified.

Recent findings: : Recent studies using next-generation genetic analytic methods confirm that FCH has a polygenic basis, with a clear large contribution from the accumulation of small-to-moderate effect common single nucleotide polymorphisms (SNPs) throughout the genome that is associated with raising TG, and probably also those raising LDL cholesterol. On the other hand, rare monogenic variants, such as those causing familial hypercholesterolemia, play a negligible role, if any. Genetic profiling suggests that patients with FCH and hypertriglyceridemia share a strong polygenic basis and show a similar profile of multiple TG-raising common SNPs.

Summary: : Recent progress in genomics has shown that most if not all of the genetic susceptibility to FCH is polygenic in nature. Future research should include larger cohort studies, with wider ancestral diversity, ancestry-specific polygenic scores, and investigation of epigenetic and lifestyle factors to help further elucidate the causative agents at play in cases where the genetic etiology remains to be defined.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cholesterol, LDL
  • Humans
  • Hyperlipidemia, Familial Combined* / genetics
  • Hyperlipidemias* / genetics
  • Multifactorial Inheritance / genetics
  • Triglycerides / genetics

Substances

  • Cholesterol, LDL
  • Triglycerides